Biolegend, 115538, Brilliant Violet 421™ anti-mouse CD19 Antibody, 500microl

CD19 is a 95 kD glycoprotein also known as B4. It is a member of the Ig superfamily, expressed on all pro-B to mature B cells (during development) and follicular dendritic cells. Plasma cells do not express CD19. CD19, in association with CD21 and CD81, forms a molecular complex integral to B cell activation.
500microl
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Mouse CD19-expressing K562 human erythroleukemia cells
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration: µg sizes: 0.2 mg/mLµL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality testedIHC-F - Verified
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤ 0.25 µg per million cells in 100 µl volume. For immunofluorescent staining using µl sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. For immunohistochemistry on Frozen tissue using the µg size, a concentration range of 1.0 - 5.0 µg/ml is suggested. It is recommended that the reagent be titrated for optimal performance for each application. Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd. Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser: Violet Laser (405 nm)
Application Notes: Additional reported applications (for the relevant formats) include: immunofluorescence7.
Application References(PubMed link indicates BioLegend citation): Shoham T, et al. 2003. J. Immunol. 171:4062. (FC) Goodyear CS, et al. 2004. J. Immunol. 172:2870. (FC) Kamimura D, et al. 2006. J. Immunol. 177:306. (FC) Andoniou CE, et al. 2005. Nat. Immunol. 6:1011. (FC) Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC) Phan TG, et al. 2007. Nat. Immunol. 8:992. (FC) Hayashida K, et al. 2008. J. Biol. Chem. 283:19895. (IF) PubMed Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed Stadnisky MD, et al. 2011. Blood. 117:5133. (FC) PubMed Perlot T, et al. 2012. J. Immunol. 188:1201. (FC) PubMed Olive V, et al. 2013. Elife. 2:822. PubMed Miyai T, et al. 2014. PNAS. 111:11780. PubMed
Product Citations: Michela Miani et al. 2018. Cell metabolism. 28(4):557-572 . PubMed Djokić V, et al. 2019. Front Immunol. 9:2891. PubMed Jiang W, et al. 2017. Sci Rep. 7:6501. PubMed Bermea KC, et al. 2022. J Vis Exp. . PubMed Christian DA, et al. 2022. Sci Immunol. 7:eabq7432. PubMed Caradonna TM, et al. 2022. Cell Rep. 41:111628. PubMed Yazicioglu YF, et al. 2023. Nat Immunol. 24:991. PubMed Doloff JC, et al. 2023. Sci Adv. 9:eade9488. PubMed Blanco LP, et al. 2022. Arthritis Rheumatol. 74:1971. PubMed Ostendorf BN, et al. 2022. Nature. 611:346. PubMed Nettersheim FS, et al. 2023. Front Cardiovasc Med. 9:1076808. PubMed Ma Y, et al. 2022. Am J Physiol Heart Circ Physiol. 322:H622. PubMed Rosalia R, et al. 2013. Immunobiology. 218:851. PubMed Yilmaz B, et al. 2021. Cell Host Microbe. 29(4):650-663.e9. PubMed Minutti CM, et al. 2019. Immunity. 50:645. PubMed Kim CJ, et al. 2018. Immunity. 49:1034. PubMed Sangesland M, et al. 2020. Immunity. 51(4):735-749. PubMed Park JG, et al. 2021. iScience. 24(9):102941. PubMed Britton GJ et al. 2019. Immunity. 50(1):212-224 . PubMed Zhang X, et al. 2022. Pharmaceutics. 14:. PubMed Kawakami R, et al. 2021. Immunity. 54(5):947-961.e8. PubMed Jackson-Jones LH, et al. 2020. Immunity. 52:700. PubMed Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed Weber G, et al. 2014. J Exp Med. 211:1243. PubMed Webster P, et al. 2018. Nat Commun. 9:2649. PubMed Lee CG, et al. 2019. JCI Insight. 4:5. PubMed Brown CC, et al. 2020. Cell. 179(4):846-863.e24.. PubMed Zheng Z, et al. 2020. Cell Reports. 31(13):107819. PubMed Schoeler K, et al. 2019. FEBS J. 10.1111/febs.14934. PubMed Prooyen N, et al. 2016. PLoS One. 12: 1005749. PubMed Dibra D, et al. 2016. Clin Cancer Res. 22: 3876 - 3883. PubMed Puigdelloses M, et al. 2021. J Immunother Cancer. 9:. PubMed Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed Giampazolias E, et al. 2021. Cell. . PubMed Bello A, et al. 2021. Immunol Cell Biol. 99:879. PubMed Xu G, et al. 2020. Cell Rep. 32:108170. PubMed He C, et al. 2022. Nat Commun. 13:5459. PubMed Kerkhofs D, et al. 2020. Theranostics. 7.022222222. PubMed Alexander Mildner et al. 2017. Immunity. 46(5):849-862 . PubMed Akoolo L, et al. 2021. Cell Microbiol. 23:e13350. PubMed Kiss M, et al. 2020. Cancer Immunol Res. 9:309. PubMed Heil J, et al. 2021. Nat Commun. 12:6963. PubMed Kelley WJ, et al. 2022. JCI Insight. 7: . PubMed Wang Y, et al. 2020. Immunity. 53(6):1151-1167.e6. PubMed Fleskens V, et al. 2019. Cell Rep. 26:3600. PubMed Jolly A, et al. 2022. Cell Rep Methods. 2:100315. PubMed Boulch M, et al. 2021. Sci Immunol. 6:. PubMed Monzon-Casanova E, et al. 2021. Eur J Immunol. 51:2266. PubMed Sadtler K, et al. 2017. Tissue Eng Part A. 23:1044. PubMed Schaum N, et al. 2020. Nature. 583:596. PubMed Kleiman E, et al. 2016. Proc Natl Acad Sci U S A. 113: E3911 - E3920. PubMed Steinmetz TD, et al. 2021. Autophagy. 17:2238. PubMed
RRID: AB_10895761 (BioLegend Cat. No. 115537) AB_2563066 (BioLegend Cat. No. 115549) AB_11203527 (BioLegend Cat. No. 115538)
Structure: Ig superfamily, associates with CD21 and CD81, 95 kD
Distribution: Pro-B cells to mature B cells (during development), follicular dendritic cells
Function: Modulates B cell activation and differentiation
Ligand/Receptor: CD21, CD81, Leu-13
Cell Type: B cells, Dendritic cells
Biology Area: Costimulatory Molecules, Immunology
Molecular Family: CD Molecules
Antigen References: 1. Fearon DT. 1993. Curr. Opin. Immunol. 5:341. 2. Krop I, et al. 1996. Eur. J. Immunol. 26:238. 3. Krop I, et al. 1996. J. Immunol. 157:48. 4. Tedder TF, et al. 1994. Immunol. Today 15:437.
Gene ID: 12478
UniProt: View information about CD19 on UniProt.org
Clone: 6D5
Regulatory Status: RUO
Other Names: B4
Isotype: Rat IgG2a, κ
Q: What is the F/P ratio range of our BV421™ format antibody reagents?
A: It is lot-specific. On average it ranges between 2-4.